SCHEMBL4163008

SCHEMBL4163008

CCOc1ccc(CC(N)=O)cc1OC

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.63
TSHR P16473 1/20 0.56
CALM1 P0DP23 3/20 0.54
GAA P10253 3/20 0.53
MAPT P10636 2/20 0.53
KDM4E B2RXH2 1/20 0.53
LMNA P02545 3/20 0.52
NPC1 O15118 1/20 0.52
HTT P42858 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
EPHX2 P34913 1/20 0.52
MEN1 O00255 1/20 0.51
HPGD P15428 1/20 0.51
KMT2A Q03164 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
TDP1 Q9NUW8 1/20 0.50
ABL1 P00519 1/20 0.50
RIN1 Q13671 1/20 0.50
ALDH1A1 P00352 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4638474 0.95 MAPK1 (0.56) MAPK1TSHRGAAMAPTKDM4E
SCHEMBL29463761 0.92 ALDH1A1 (0.57) MAPK1MAPTKDM4ELMNAHTT
SCHEMBL28293832 0.92 ALDH1A1 (0.57) MAPK1MAPTKDM4ELMNAHTT
SCHEMBL29602721 0.90 LMNA (0.61) MAPK1GAAMAPTKDM4ELMNA
SCHEMBL1033641 0.90 LMNA (0.61) MAPK1GAAMAPTKDM4ELMNA
SCHEMBL3527450 0.86 CA5A (0.64) MAPK1TSHRCALM1GAAMAPT
SCHEMBL30447349 0.85 PTGER3 (0.53) GAAMAPTKDM4ELMNANPC1
SCHEMBL10701749 0.85 PTGER3 (0.53) GAAMAPTKDM4ELMNANPC1
SCHEMBL18887599 0.84 TSHR (0.56) MAPK1TSHRCALM1GAAMAPT
SCHEMBL3782064 0.83 LMNA (0.55) MAPK1TSHRCALM1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074089-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2013-09-18 EP claimed
US-8222248-B2 Organic compounds NOVARTIS AG (CH) 2012-07-17 US claimed
EP-2074089-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2009-07-01 EP claimed
WO-2008048991-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-04-24 WO claimed
EP-2074089-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2013-09-18 EP disclosed
US-8222248-B2 Organic compounds NOVARTIS AG (CH) 2012-07-17 US disclosed
US-6930107-B2 6-azauracil derivatives as thyroid receptor ligands PFIZER INC. (US) 2005-08-16 US disclosed
EP-1088819-B1 6-azauracil derivatives as thyroid receptor ligands PFIZER PROD INC (US) 2005-06-15 EP disclosed
US-6787652-B1 LOWERING LIPIDS AND SERUM CHOLESTEROL WITHOUT GENERATING ADVERSE CARDIAC EFFECTS; 4,5-DIHYDRO-3,5-DIOXO-1,2,4-TRIAZINE DERIVATIVES PFIZER, INC. 2004-09-07 US disclosed
US-20040157844-A1 6-azauracil derivatives as thyroid receptor ligands DOW ROBERT L (US) 2004-08-12 US disclosed
EP-1088819-A2 6-azauracil derivatives as thyroid receptor ligands Pfizer Products Inc. (US) 2001-04-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157844-A1 6-azauracil derivatives as thyroid receptor ligands TSHR, THRA, THRB MAPK1 1504/4885TSHR 1/4885CALM1 3956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.